Table 2.
| Therapy | No. of trials | Geography | Randomized (%) | Blinding (%) | |
|---|---|---|---|---|---|
| Remdesivir | 8 | Global | 7 (88) | None | 4 (50) |
| Single | 0 (0) | ||||
| Multi | 4 (50) | ||||
| Favipiravir | 18 | Global | 18 (100) | None | 11 (61) |
| Single | 1 (6) | ||||
| Multi | 6 (33) | ||||
| Lopinavir/ritonavir | 24 | Global | 21 (88) | None | 17 (71) |
| Single | 2 (8) | ||||
| Multi | 5 (21) | ||||
| Tocilizumab/baricitinib/ruxolitinib/sarilumab/dexamethasone | 64 | Global | 44 (69) | None | 48 (75) |
| Single | 1 (2) | ||||
| Multi | 15 (23) | ||||
| Chloroquine, hydroxychloroquine | 134 | Global | 123 (92) | None | 65 (49) |
| Single | 10 (7) | ||||
| Multi | 59 (44) | ||||
| Convalescent plasma | 81 | Global | 49 (60) | None | 62 (77) |
| Single | 2 (2) | ||||
| Multi | 17 (21) | ||||
| Ivermectin | 26 | Global | 24 (92) | None | 12 (46) |
| Single | 3 (12) | ||||
| Multi | 11 (42) | ||||
| Low-dose radiation | 12 | United States, Italy, India, Spain, Iran | 3 (25) | None | 11 (92) |
| Single | 0 (0) | ||||
| Multi | 1 (8) | ||||
| Other | 838 | ||||
a
COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory distress syndrome coronavirus 2; 2019-nCoV = 2019 novel coronavirus.
b
Total recruiting/open interventional trials (1154) listed from a search of ClinicalTrials.gov on June 29, 2020, using a condition/disease query of COVID-19, SARS-CoV-2, and 2019-nCoV.